Topic: cell manufacturing
Abzena will invest $20 million in a cell manufacturing facility, and Catalent is spending $2.5 million on a clinical supply facility in China.
Astellas will invest $255 million in production and R&D as it pushes into gene and cell therapies for cancer and other diseases.
Another cell manufacturing facility will be built in the U.S., this by a transatlantic biotech in which GlaxoSmithKline owns a sizable share.
Novartis is looking ahead to China for introduction of its CAR-T treatment Kymriah with a deal for manufacturing there.
Novartis’ traditional pill manufacturing will shoulder the brunt of a cost-cutting effort announced Tuesday as it looks to a future in biologic drugs.
Biotech Rubius Therapeutics will invest large chunk of its recently raised $220 million to build a manufacturing facility.
Atara Biotherapeutics has initiated construction of a new CAR-T gene therapy manufacturing facility.
Lonza opened the world’s biggest manufacturing plant for cell and gene therapies targeting rare genetic disorders or life-threatening diseases.
Merck KGaA, which has been rapidly building up its manufacturing and distribution capabilities in China, says it will now expand further in Asia.
Gritstone Oncology, which focuses on personalized cancer immunotherapy, opened a new biomanufacturing facility in Pleasanton, CA, to produce the company’s first investigational products.